The Denver Business Journal details our recent acquisition of Emvenio Research, and our second acquisition of 2024.

In partnership with GlobalData, PCM Trials recently hosted a live webinar that offered a look into the evolution and future of decentralized clinical trials (DCTs).

Denver (February 23, 2024) – Denver-based PCM Trials, the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs), today announced the acquisition of EmVenio Research based in Durham, North Carolina.

PCM Trials expands its global footprint PCM Trials President Greg Austin spoke with the Denver Business Journal last week about the company’s recent acquisition of Netherlands-based Clinical Trial Service (CTS).

Denver (January 10, 2024) – PCM Trials, a Denver, USA-based leader in providing mobile research nurses for decentralized clinical trials, today announced the acquisition of Clinical Trial Service (CTS).

On November 14, 2023, industry experts from PCM Trials were joined by trusted logistics vendors for a live webinar featuring lively conversation about overcoming challenges to successfully deliver compliant mobile visits around the world.

The clinical trial industry is literally exploding, launching more trials within shorter windows, adding new players, incorporating new technologies and meeting unprecedented regulatory challenges.

Decentralized trials (DCTs) have grown in acceptance since the COVID pandemic when mobile research nurses were asked to step in and save hundreds of site-based clinical trials that were in jeopardy of being postponed or cancelled because of mandated lockdowns and fear of spreading the virus.

Fully Decentralized Trials: Aspirational Goal Or Reality? The COVID pandemic accelerated the adoption of decentralized trials at a rate never before experienced throughout the Biopharma industry. Sponsors and CROs who

Given the experience of the past few years, more sponsors and CROs are incorporating DCT methods into their protocols while others are at least considering it, in part to benefit from the many advantages of DCTs as well as to avoid disruptions to future studies. While there’s no such thing as pandemic-proofing a study, building home visits into a study often is a smart choice.